TransEnterix, Inc. (TRXDW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TransEnterix, Inc. (TRXDW) trades at $0.15 with AI Score 53/100 (Grade B). Asensus Surgical, Inc. (TRXDW) is a medical device company focused on enhancing minimally invasive surgery through its Senhance System. Market cap: $40.09M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for TRXDW: TRXDW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TRXDW against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TRXDW: the 7 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →TransEnterix, Inc. (TRXDW) Healthcare & Pipeline Overview
Asensus Surgical, Inc. (TRXDW) develops and sells robotic surgical devices, including the Senhance System, aimed at improving minimally invasive surgery. The company operates globally, focusing on digitizing the surgical interface to enhance precision and outcomes, but faces challenges typical of small-cap medical device companies in a competitive market.
What Is the Investment Thesis for TRXDW?
Investing in Asensus Surgical (TRXDW) presents a high-risk, high-reward scenario. The company's Senhance System offers a potentially disruptive technology in the robotic surgery market, aiming to improve surgical precision and patient outcomes. However, the company's negative profit margin of -914.5% and gross margin of -58.7% indicate significant financial challenges. Key growth catalysts include expanding the installed base of Senhance Systems and increasing utilization rates per system. The company's ability to secure additional funding and achieve profitability will be critical for long-term success. Investors should carefully weigh the potential benefits of the technology against the financial risks associated with a small-cap company operating in a competitive market.
Based on FMP financials and quantitative analysis
TRXDW Key Highlights
- Market capitalization of $40.09M, classifying it as a micro-cap stock.
- Negative P/E ratio of -0.48, reflecting current losses and the absence of positive earnings.
- Profit margin of -914.5%, indicating substantial operational losses.
- Gross margin of -58.7%, suggesting that the cost of goods sold exceeds revenue.
- Beta of 1.41, indicating higher volatility compared to the overall market.
Who Are TRXDW's Competitors?
TRXDW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACOGF Alpha Cognition Inc. | $5.72 | +0.00% | $35.66M | 50 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| CSWYY China Shineway Pharmaceutical Group Limited | $19.25 | +0.00% | $36.35M | 43 |
| DMTTF Small Pharma Inc. | $0.11 | -9.69% | $37.51M | 44 |
| SI SHOULDER INNOVATIONS, INC. | $21.14 | -0.61% | $438.41M | 59 |
| ACIXF Acarix AB (publ) | $0.03 | -3.57% | $31.28M | 52 |
| BMXXY bioMérieux S.A. | $7.53 | -6.98% | $8.88B | 46 |
| EBRCZ EBR Systems, Inc. | $0.31 | +0.00% | $194.77M | 45 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRXDW's Key Strengths?
- Innovative Senhance System technology.
- Potential to improve surgical precision and patient outcomes.
- Global market presence.
- Experienced management team.
What Are TRXDW's Weaknesses?
- Significant financial losses.
- Negative gross margin.
- Limited market share compared to larger competitors.
- Reliance on a single product line.
What Could Drive TRXDW Stock Higher?
- Expansion into new surgical specialties, increasing the addressable market for the Senhance System.
- Regulatory approvals in new geographic markets, enabling geographic expansion.
- Increased utilization of existing Senhance Systems through training and support.
- Development and launch of new instruments and accessories for the Senhance System.
- Strategic partnerships and collaborations with other companies in the medical device industry.
What Are the Key Risks for TRXDW?
- Financial-distress signal — its Altman Z-Score of -42.57 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the robotic surgery market, such as Intuitive Surgical.
- Technological advancements by competitors that could render the Senhance System obsolete.
- Regulatory hurdles and reimbursement challenges that could limit market access.
- Economic downturns affecting hospital capital spending, reducing demand for the Senhance System.
- Significant financial losses and negative gross margin, raising concerns about the company's long-term viability.
What Are the Growth Opportunities for TRXDW?
- Expansion into New Surgical Specialties: Asensus Surgical has the opportunity to expand the application of its Senhance System into new surgical specialties beyond general surgery and gynecology. This could include areas such as urology, thoracic surgery, and pediatric surgery. Each new specialty represents a potential market expansion, increasing the addressable market for the Senhance System. The timeline for this growth opportunity is ongoing, as the company continues to develop and refine its technology for different surgical applications. Success depends on demonstrating the Senhance System's effectiveness and safety in these new areas.
- Geographic Expansion: Asensus Surgical can pursue growth by expanding its geographic presence into new markets, particularly in Asia-Pacific and Latin America. These regions offer significant growth potential due to their large populations, increasing healthcare spending, and growing adoption of advanced medical technologies. The timeline for this expansion is medium-term, requiring regulatory approvals and the establishment of distribution networks. Success hinges on adapting the company's marketing and sales strategies to the specific needs of each region.
- Increased Utilization of Existing Systems: A key growth driver is increasing the utilization rate of the Senhance Systems already installed in hospitals. This can be achieved by providing comprehensive training and support to surgeons, promoting the benefits of the Senhance System, and expanding the range of procedures that can be performed using the system. The timeline for this growth opportunity is immediate and ongoing, as the company continuously works to improve system utilization. Success depends on demonstrating the value of the Senhance System to surgeons and hospital administrators.
- Development of New Instruments and Accessories: Asensus Surgical can drive growth by developing and launching new instruments and accessories for the Senhance System. This includes specialized instruments for different surgical procedures, as well as advanced imaging and visualization technologies. The timeline for this growth opportunity is medium-term, as it requires research, development, and regulatory approvals. Success depends on identifying unmet needs in the surgical market and developing innovative solutions that address those needs.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other companies in the medical device industry can accelerate Asensus Surgical's growth. This could include partnerships with companies that specialize in imaging, navigation, or other surgical technologies. These partnerships can provide access to new markets, technologies, and expertise. The timeline for this growth opportunity is ongoing, as the company continuously seeks out potential partnerships. Success depends on identifying synergistic partners and structuring mutually beneficial agreements.
What Opportunities Does TRXDW Have?
- Expansion into new surgical specialties.
- Geographic expansion into emerging markets.
- Increased utilization of existing systems.
- Development of new instruments and accessories.
What Threats Does TRXDW Face?
- Competition from established players in the robotic surgery market.
- Technological advancements by competitors.
- Regulatory hurdles and reimbursement challenges.
- Economic downturns affecting hospital capital spending.
What Are TRXDW's Competitive Advantages?
- Proprietary robotic surgery technology with the Senhance System.
- Intellectual property protection through patents and trademarks.
- Established relationships with hospitals and surgeons.
- First-mover advantage in certain market segments.
What Does TRXDW Do?
Asensus Surgical, Inc., formerly known as TransEnterix, Inc., was founded with the mission of revolutionizing minimally invasive surgery (MIS) through advanced robotics. The company changed its name in February 2021 to reflect its evolved focus. Its core product, the Senhance System, is a multi-port robotic surgery platform that allows surgeons to control up to four robotic arms and a camera during laparoscopic procedures. This system is designed to provide enhanced precision, control, and visualization compared to traditional laparoscopic techniques. In addition to the Senhance System, Asensus Surgical offers a range of instruments, including 3mm diameter instruments, hooks, and articulating instruments, as well as the Senhance ultrasonic system for tissue ligation and division. The company's geographic reach extends across the United States, Europe, the Middle East, Africa, and Asia, where it markets and sells its products to hospitals and surgical centers. Asensus Surgical aims to digitize the interface between the surgeon and the patient, enabling performance-guided surgery that delivers improved outcomes. The company is headquartered in Durham, North Carolina, and employs 207 individuals.
What Products and Services Does TRXDW Offer?
- Develops and sells the Senhance System, a multi-port robotic surgery system.
- Offers instruments and accessories for use with the Senhance System, including 3mm and 5mm hooks.
- Provides the Senhance ultrasonic system for tissue ligation and division.
- Digitizes the interface between surgeons and patients for performance-guided surgery.
- Enhances minimally invasive surgery (MIS) through robotic technology.
- Markets its products in the United States, Europe, the Middle East, Africa, and Asia.
How Does TRXDW Make Money?
- Sells the Senhance System to hospitals and surgical centers.
- Generates revenue from the sale of instruments and accessories used with the Senhance System.
- Provides service and maintenance contracts for the Senhance System.
- Expands product offerings through research and development.
What Industry Does TRXDW Operate In?
Asensus Surgical operates in the competitive medical device industry, specifically within the robotic surgery segment. This market is characterized by technological innovation, stringent regulatory requirements, and the need for significant capital investment. Key trends include the increasing adoption of minimally invasive surgical techniques and the growing demand for robotic-assisted surgery. The company competes with larger, more established players in the robotic surgery market, such as Intuitive Surgical. The global surgical robotics market is projected to reach billions of dollars in the coming years, driven by factors such as an aging population and advancements in surgical technology.
Who Are TRXDW's Key Customers?
- Hospitals and surgical centers.
- Surgeons performing minimally invasive procedures.
- Patients undergoing robotic-assisted surgery.
F-Score 3/9Financial Health
TransEnterix, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -42.57 places it in the distress zone, a signal of elevated financial risk.
TransEnterix, Inc. (TRXDW) Valuation Context
Valued at $40.09M, TRXDW is classified as a micro-cap stock. Relative to its peer group, TRXDW's quantitative score of 53/100 is roughly in line with the peer average of 52/100.
Company Profile
TransEnterix, Inc. operates in the Medical - Specialties industry within the Healthcare sector. The company is led by CEO Anthony Fernando.
TRXDW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative Senhance System technology.
- Potential to improve surgical precision and patient outcomes.
- Global market presence.
- Experienced management team.
Bear Case
- Significant financial losses.
- Negative gross margin.
- Limited market share compared to larger competitors.
- Reliance on a single product line.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
TRXDW Latest News
No recent news available for TRXDW.
TRXDW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TRXDW.
Price Targets
Wall Street price target analysis for TRXDW.
TRXDW MoonshotScore
What does this score mean?
The MoonshotScore rates TRXDW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Anthony Fernando
CEO
Anthony Fernando serves as the CEO of Asensus Surgical, bringing extensive experience in the medical device industry. His background includes leadership roles at prominent medical technology companies, where he focused on driving innovation and commercial growth. He has a proven track record of successfully launching new products and expanding market share. Fernando's expertise spans across various areas, including sales, marketing, and product development. His strategic vision is centered on advancing robotic surgery and improving patient outcomes through technological innovation.
Track Record: Since becoming CEO, Anthony Fernando has focused on refining Asensus Surgical's strategic direction, emphasizing the unique capabilities of the Senhance System. Key milestones under his leadership include expanding the system's applications in different surgical specialties and securing regulatory approvals in new markets. He has also prioritized strengthening the company's relationships with key opinion leaders and driving increased utilization of the Senhance System in existing customer accounts.
TRXDW OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Asensus Surgical (TRXDW) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier also typically implies higher risks due to the potential for less stringent regulatory oversight and greater information asymmetry compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure compared to exchange-listed companies.
- Higher price volatility due to lower trading volume.
- Potential for wider bid-ask spreads, increasing transaction costs.
- Greater risk of fraud or manipulation due to less regulatory oversight.
- Difficulty in obtaining reliable information about the company's operations and financial condition.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Review any legal or regulatory issues facing the company.
- Monitor trading volume and price activity for signs of manipulation.
- Consult with a qualified financial advisor.
- Experienced CEO with a background in the medical device industry.
- Patented Senhance System technology.
- Global market presence with sales in multiple regions.
- Focus on improving surgical precision and patient outcomes.
- History as a formerly exchange-listed company (TransEnterix).
TransEnterix, Inc. Healthcare Stock: Key Questions Answered
What does TransEnterix, Inc. do?
Asensus Surgical, Inc. (formerly TransEnterix) is a medical device company specializing in robotic-assisted surgery. Its primary product is the Senhance System, a multi-port robotic surgery platform designed to enhance minimally invasive surgery. The Senhance System allows surgeons to control robotic instruments and a camera during laparoscopic procedures, aiming to improve precision, control, and visualization. The company also offers a range of instruments and accessories for use with the Senhance System, as well as the Senhance ultrasonic system for tissue ligation and division. Asensus Surgical markets and sells its products globally.
What do analysts say about TRXDW stock?
Analyst coverage of Asensus Surgical (TRXDW) is limited due to its small market capitalization and OTC listing. Generally, analysts recognize the potential of the Senhance System to improve surgical outcomes and expand the adoption of robotic-assisted surgery. However, they also acknowledge the significant financial challenges facing the company, including its negative profit margin and reliance on external funding. The consensus view is that TRXDW is a high-risk, high-reward investment, with success dependent on the company's ability to execute its growth strategy and achieve profitability.
What are the main risks for TRXDW?
Asensus Surgical (TRXDW) faces several key risks. These include intense competition from larger, more established players in the robotic surgery market, such as Intuitive Surgical. The company also faces technological risks, as competitors may develop more advanced or cost-effective surgical technologies. Financial risks are also significant, given the company's history of losses and need for additional capital. Regulatory risks include the potential for delays or denials in obtaining regulatory approvals for new products or indications. Finally, market adoption risks exist, as surgeons and hospitals may be hesitant to adopt the Senhance System due to its cost or perceived lack of advantages over existing technologies.
What are the key factors to evaluate for TRXDW?
TransEnterix, Inc. (TRXDW) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does TRXDW data refresh on this page?
TRXDW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TRXDW's recent stock price performance?
TransEnterix, Inc. (TRXDW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Senhance System technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRXDW overvalued or undervalued right now?
Valuing TransEnterix, Inc. (TRXDW) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TRXDW?
Before investing in TransEnterix, Inc. (TRXDW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be less reliable than exchange-listed data.
- Analyst opinions are based on limited coverage.